Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study.
Olsson AG, Lindahl C, Holme I, Fayyad R, Faergeman O, Kastelein JJ, Tikkanen MJ, Larsen ML, Pedersen TR; Incremental Decrease in End Points Through Aggressive Lipid Lowering Study Group. Olsson AG, et al. Among authors: fayyad r. Eur J Cardiovasc Prev Rehabil. 2011 Apr;18(2):262-9. doi: 10.1177/1741826710389391. Epub 2011 Feb 8. Eur J Cardiovasc Prev Rehabil. 2011. PMID: 21450674 Clinical Trial.
Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials.
Bangalore S, Fayyad R, Hovingh GK, Laskey R, Vogt L, DeMicco DA, Waters DD; Treating to New Targets Steering Committee and Investigators. Bangalore S, et al. Among authors: fayyad r. Am J Cardiol. 2014 Jun 15;113(12):2018-20. doi: 10.1016/j.amjcard.2014.03.046. Epub 2014 Apr 3. Am J Cardiol. 2014. PMID: 24793673 Review.
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial.
Tikkanen MJ, Szarek M, Fayyad R, Holme I, Cater NB, Faergeman O, Kastelein JJ, Olsson AG, Larsen ML, Lindahl C, Pedersen TR; IDEAL Investigators. Tikkanen MJ, et al. Among authors: fayyad r. J Am Coll Cardiol. 2009 Dec 15;54(25):2353-7. doi: 10.1016/j.jacc.2009.08.035. J Am Coll Cardiol. 2009. PMID: 20082922 Free article. Clinical Trial.
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels.
Tikkanen MJ, Fayyad R, Faergeman O, Olsson AG, Wun CC, Laskey R, Kastelein JJ, Holme I, Pedersen TR; IDEAL Investigators. Tikkanen MJ, et al. Among authors: fayyad r. Int J Cardiol. 2013 Oct 9;168(4):3846-52. doi: 10.1016/j.ijcard.2013.06.024. Epub 2013 Aug 31. Int J Cardiol. 2013. PMID: 24001698 Clinical Trial.
Body-Weight Fluctuations and Outcomes in Coronary Disease.
Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Bangalore S, et al. Among authors: fayyad r. N Engl J Med. 2017 Apr 6;376(14):1332-1340. doi: 10.1056/NEJMoa1606148. N Engl J Med. 2017. PMID: 28379800 Free article. Clinical Trial.
82 results